- Home
- CYCN vs BIAF Comparison
CYCN vs BIAF Comparison
Compare CYCN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | BIAF |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CYCN | BIAF |
|---|---|---|
| Price | $1.44 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 78.0K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,855,000.00 | ★ $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1371.65 | N/A |
| 52 Week Low | $1.28 | $1.18 |
| 52 Week High | $6.25 | $46.53 |
Technical Indicators
Market Signals| Indicator | CYCN | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 34.25 |
| Support Level | $1.41 | $1.18 |
| Resistance Level | $1.64 | $1.74 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 21.27 | 12.36 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.